New clinical data suggests that the Johnson & Johnson pharmaceutical arm confirms that its candidate vaccine COVID-19 was able to stimulate an immune response that lasted just over two months, or 71 days, among 805 study participants.
Announced through a Press release and published in The new English medical journal, the company said its vaccine, called Ad26.COV2.S, elicited an immune response against COVID-19 antibodies after a single dose.
Other approved COVID-19 vaccines from Pfizer and Moderna require two inoculations a few weeks apart. Taking just one shot would result in less immunity.
WHAT EXPERTS ARE SAYING ABOUT VACCINATION EFFORTS
CDC EMPLOYEES ENSURE THE SAFETY OF COVID-19 VACCINES IN spite of ADVERSE REACTIONS
NEW YORK WEIGHT IF WE CAN BE EXCLUDED IN THE CUTTING OF THE COVID-19 VACCINE LINE
THE EX-FDA CHIEF THINKS THE HIGHLY CONTAGIOUS MUTATION OF COVID-19 IS ‘ALREADY IN THE USA’
Johnson & Johnson claims that only one injection of Ad26.COV2.S produces strong neutralizing antibodies in more than 90 percent of its clinical trial volunteers.
These neutralizing antibodies act to prevent proteins from the virus from binding to human cells. A two-dose regimen was less reactogenic, but it triggered twice as many antibodies.
The next phase 3 clinical trials, the final stage of vaccine testing, will confirm whether a second dose will provide additional benefits of effectiveness or durability, especially in the elderly.
“Although all ongoing Phase 3 studies of other Covid-19 vaccines have evaluated two dose schedules, a single dose of Ad26.COV2.S elicited a strong humoral response in most vaccine recipients, with the presence of S and neutralizing antibodies in more than 90% of participants, regardless of age or vaccine dose, ”says the published report.
Five serious adverse side effects have been reported, including one participant temporarily hospitalized with fever. Other common adverse effects were migraines, myalgia, fatigue and pain at the injection site.
While the U.S. government struggles to allocate the vaccine doses available to the initial populations, a single dose vaccine that is effective against exposure to COVID-19 “has obvious logistical advantages over a two-dose vaccine, especially during a pandemic. ”, Affirm the authors of the study.
This may be due to the way the vaccine is made. CNN Notes that instead of using mRNA to communicate with human cells and arm them against COVID-19 pathogens, the Johnson & Johnson candidate presents a weakened version of the common cold called adenovirus 26 to elicit an immune response to help the body recognize and combat COVID-19 particles.
Johnson & Johnson recognized notably that the lack of minority groups characterized the representation of study participants.
Despite promising results in the first tests, The New York Times writes that the company is lagging behind in production, leaving the federal government waiting for more than 60 million doses. The company may be able to resume production in March.
CHINA WUHAN CDC SUGGESTION STUDY MAY HAVE 10 MANY COVID-19 CASES REPORTED
A NEW CORONAVIRUS VARIANT IN THE UNITED KINGDOM: WHAT YOU NEED TO KNOW
FROM THE LABORATORY BENCH TO THE UPPER ARM: HOW THE COVID-19 VACCINES ENTERED BEING
5,000 BAGS FOR BODY AND 60 MORGUE TRUCKS SHIPPED TO COVID-RAVAGED CALIFORNIA